Introduction
Inflammatory bowel disease (IBD) is a chronic, non-specific intestinal inflammatory disease that involves the ileum, rectum, colon and even the entire digestive tract and includes mainly ulcerative colitis (UC) and Crohn’s disease (CD). The main clinical manifestations are abdominal pain, diarrhoea, haematochezia and weight loss. This disease is characterised by a lengthy course and can persist for a lifetime. IBD is a growing global health concern, and its prevalence is highest in developed Western countries.1 However, the incidence rate of IBD in Asia and Eastern Europe has steadily increased over the last decade.2
Previous studies have confirmed that patients with IBD present with dyslipidaemia,3 4 which is a well-established risk factor for cardiovascular disease. Several studies have shown that lower total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B) and apolipoprotein A-I (Apo A-I) levels are associated with higher triglyceride (TG) and lipoprotein (a) (Lp(a)) levels in patients with IBD,5–10 which are independently associated with more severe disease.7 9 10 Additionally, compared with the general population, male patients with IBD have higher TG levels, while female patients with IBD have significantly lower TG levels.7 However, one study indicated that patients with IBD have lower TG levels than healthy controls and that the Crohn’s Disease Activity Index (CDAI) and Mayo score are not correlated with TG. In contrast, TC, HDL-C and LDL-C levels are negatively associated with the CDAI.11 Another study involving 497 patients with UC yielded similar results, indicating no significant correlation between TG levels and disease activity.12 One study revealed that the Lp(a) level in patients with IBD was not significantly different from that in controls.13 The results of studies on the relationship between IBD and serum lipid profiles are inconsistent, and they are cross-sectional studies, making it impossible to draw causal inferences about the relationship between IBD and serum lipid profiles. Currently, longitudinal prospective studies that thoroughly evaluate the correlation between IBD incidence and serum lipid profiles are rare, and the results are inconsistent or even contradictory.14–16
Mendelian randomisation (MR) analysis used genetic variants as non-confounded surrogates of the exposure and evaluates whether the exposure may have a causal effect on an outcome of interest. In an MR study, confounding and reverse causality are minimised, enabling plausible causal inferences. To investigate the causal relationship, we conducted an MR analysis to determine if the two attributes are causally correlated and, if so, the direction of correlation (ie, positive or negative). In an MR analysis, single nucleotide polymorphisms (SNPs) strongly associated with the exposure (eg, TG levels) are considered instrumental variables (IVs) for estimating the causal effects of the exposure on the outcome (eg, IBD). Such studies may aid in understanding the complex interplay between these variables and facilitate disease prevention and early intervention. This study aimed to explore the causal relationship between serum lipid profiles and IBD through MR analysis, shedding light on their interactions and offering guidance for clinical practice.